Advertisement

Topics

Kura Oncology Inc KURA Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 17022017] Prices from USD $250

01:18 EST 10 Mar 2017 | BioPortfolio Reports

Summary

Kura Oncology Inc Kura Oncology discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company's lead drug candidate, Tipifarnib, an inhibitor of protein farnesylation, is a small molecule that targets oncogenes or signaling pathways that drive cancer growth. Tipifarnib HRAS Mutant Solid Tumors HRAS, Tipifarnib Peripheral TCell LymphomaPTCL, Tipifarnib Myelodysplastic SyndromesMDS and Tipifarnib Chronic Myelomonocytic LeukemiaCMML are into Phase II clinical trials. Kura Oncology's preclinical stage products are KO947, a small molecule inhibitor of extracellularsignalregulated kinases 1 and 2 ERK1/2 and Menin Mixed Lineage Leukemia MLL Inhibitor Program inhibits the interaction between the proteins menin and MLL for the treatment of MLLrearranged MMLr leukemias. The company's target therapeutic areas include Tcell lymphoma, melanoma, lung and pancreatic cancers, mixed lineage leukemia and other cancers. Kura Oncology is headquartered in La Jolla, California, the US.

Kura Oncology Inc KURA Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.

GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.
Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.
Business Description A brief description of the company's operations.
Key Employees A list of the key executives of the company.
Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors A list of the key competitors of the company.
Key Recent Developments A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Original Article: Kura Oncology Inc KURA Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 17022017] Prices from USD $250

NEXT ARTICLE

More From BioPortfolio on "Kura Oncology Inc KURA Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 17022017] Prices from USD $250"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...